AstraZeneca PLC (NASDAQ:AZN) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company announced ...

This was the ADR's second consecutive day of losses.

AstraZeneca has launched a Phase I clinical study titled An Open-label, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 Followi ...

VANCOUVER, BC / ACCESS Newswire / June 27, 2025 / Onco-Innovations Limited(CBOE CA:ONCO)(Frankfurt:W1H,WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that its wholly-owned subsidiary, ...

VANCOUVER, BC / ACCESS Newswire / June 27, 2025 / Onco-Innovations Limited(CBOE CA:ONCO)(Frankfurt:W1H,WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that its wholly-owned subsidiary, I ...

AstraZeneca has announced a new clinical study titled ‘Pregnancy and Infant Outcomes in Anifrolumab Exposed Pregnancies Using PRegnancy Outcomes Intensive Monitoring (PRIM) Data ...

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said Datroway has secured US Food & Drug Administration approval for use in adult patients with previously treated advanced ...

Read about AstraZeneca PLC ADR (AZN:XNAS) stock and today's latest news and financial updates. AZN - AstraZeneca PLC ADR News | Morningstar Morningstar brands and products ...

Learn about the executive team and board of directors at AstraZeneca PLC ADR (AZN:XNAS) and review their bios and compensation over the latest fiscal years.